Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade

Journal of Urology

Volumn 168, Issue 6, 2002, Pages 2655-2658

  Böhm, Malte ^a,b   Wieland, Ilse ^a,b   Schmidt, Claus ^a,b   Rübben, Herbert ^a,b   Allhoff, Ernst Peter ^a,b  

^a Otte von Guericke University   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Bladder; Carcinoma, transitional cell; Loss of heterozygosity; Prognosis; Tumor markers, biological

Indexed keywords

TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 5P; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036893898     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64238-3     Document Type: Article

References (25)

1. Zlotta, A. R. and Schulman, C. C.: Biological markers superficial bladder tumors and their prognostic significance. Urol Clin North Am, 27: 179, 2000
2. Knowles, M. A.: What we could do now: Molecular pathology of bladder cancer. Mol Pathol, 54: 215, 2001
3. Messing, E. M. and Catalona, W.: Urothelial tumors of the urinary tract. In: Campbell's Urology, 7th Ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., vol. 3, chapt. 77, p. 2327, 1998
4. Rübben, H. and Otto, T.: Harnblasenkarzinom. In: Uroonkologie. Edited by H. Rübben. Berlin: Springer, p. 85, 2001
5. Bohm, M., Kleine-Besten, R. and Wieland, I.: Loss of heterozygosity analysis on chromosome 5p defines 5p13-12 as the critical region involved in tumor progression of bladder carcinomas. Int J Cancer, 89: 194, 2000
6. Peralta, R. C., Casson, A. G., Wang, R. N., Keshavjee, S., Redston, M. and Bapat, B.: Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. Int J Cancer, 78: 600, 1998
7. Wieland, I., Bohm, M., Arden, K. C., Ammermuller, T., Bogatz, S., Viars, C. S. et al: Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene, 12: 97, 1996
8. Mostofi, F. K., Sobin, L. H. and Torloni, H.: Histological Typing of Urinary Bladder Tumours. Geneva: World Health Organization, 1973
9. Böhm, M. and Wieland, I.: Analysis of tumour-specific alterations in native specimens by PCR: How to procure the tumour cells! Int J Oncol, 10: 131, 1997
10. Bohm, M., Wieland, I., Schutze, K. and Rubben, H.: Microbeam-MOMeNT: Non-contact laser microdissection of membrane-mounted native tissue. Am J Pathol, 151: 63, 1997
11. Bohm, M., Kirch, H., Otto, T., Rubben, H. and Wieland, I.: Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus at 5p13-12 is a prognostic marker of tumor progression. Int J Cancer, 74: 291, 1997
12. Böhm, M., Schmidt, C., Wieland, I., Leclerc, N. and Allhoff, E. P.: Membrane-based laser microdissection in molecular oncology. Onkologie, 22: 296, 1999
13. von Knobloch, R., Bugert, P., Jauch, A., Kalble, T. and Kovacs, G.: Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J Pathol, 190: 163, 2000
14. Zhao, J., Richter, J., Wagner, U., Roth, B., Schraml, P., Zellweger, T. et al: Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res, 59: 4658, 1999
15. Sidransky, D., Frost, P., Von Eschenbach, A., Oyasu, R., Preisinger, A. C. and Vogelstein, B.: Clonal origin of bladder cancer. N Engl J Med, 326: 737, 1992
16. Diaz-Cano, S. J., Blanes, A., Rubio, J., Matilla, A. and Wolfe, H. J.: Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab Invest, 80: 279, 2000
17. Richter, J., Wagner, U., Schraml, P., Maurer, R., Alund, G., Knonagel, H. et al: Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res, 59: 5687, 1999
18. Sengelov, L., Christensen, M., von der Maase, H. D., Horn, T., Marcussen, N., Kamby, C. et al: Loss of heterozygosity at lp, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome. Cancer Genet Cytogenet, 123: 109, 2000
19. Wada, T., Louhelainen, J., Hemminki, K., Adolfsson, J., Wijkstrom, H., Norming, U. et al: Bladder cancer: Allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res, 6: 610, 2000
20. Pycha, A., Mian, C., Posch, B., Haitel, A., Mokhtar, A. A., El-Baz, M. et al: Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: An alternative to classic prognostic indicators? Urology, 53: 1005, 1999
21. Grossman, H. B., Liebert, M., Antelo, M., Dinney, C. P., Hu, S. X., Palmer, J. L. et al: p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res, 4: 829, 1998
22. Uchida, A., Tachibana, M., Miyakawa, A., Nakamura, K. and Murai, M.: Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res, 28-297, 2000
23. Stein, J. P., Grossfeld, G. D., Ginsberg, D. A., Esrig, D., Freeman, J. A., Figueroa, A. J. et al: Prognostic markdrs in bladder cancer: A contemporary rdview of the literature. J Urol, 160: 645, 1998
24. Cote, R. J. and Chatterjee, S. J.: Molecular determinants of outcome in bladder cancer. Cancer J Sci Am, 5: 2, 1999
25. Reuter, V. E.: Bladder risk and prognostic factors: a pathologist's perspective. Urol Clin North Am, 26: 481, 1999